%0 Journal Article %A SANG-CHEOL LEE %A HEE-JEONG CHEONG %A SOOK-JA KIM %A JINA YOON %A HAN JO KIM %A KYOUNG HA KIM %A SE HYOUNG KIM %A HYUN JUNG KIM %A SANG BYUNG BAE %A CHAN-KYU KIM %A NAMSU LEE %A KYU TAEG LEE %A SUNG KYU PARK %A DAE SIK HONG %A HEE SOOK PARK %A JONG-HO WON %T Low-Dose Combinations of LBH589 and TRAIL Can Overcome TRAIL-resistance in Colon Cancer Cell Lines %D 2011 %J Anticancer Research %P 3385-3394 %V 31 %N 10 %X Background: Despite the considerable advances in the treatment of colorectal cancer, substantial changes in treatment strategies are required to overcome the problems of drug resistance and toxicity. Materials and Methods: Combinations of Pan-deacetylase inhibitor LBH589 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were studied in three colon cancer cell lines, HCT116, colo205, and HT29 (HCT116 and colo205 are TRAIL sensitive, whereas HT29 is TRAIL resistant). Results: It was found that TRAIL-induced cytotoxicity was enhanced by LBH589 cotreatment in the TRAIL-sensitive cell lines, and in the TRAIL-resistant HT29 cell line. The cytotoxicity of low-dose TRAIL plus LBH589 was found to be comparable to that of high-dose TRAIL plus LBH589. Additionally, TRAIL and LBH589 were significantly less toxic to normal UCB mononuclear cells than to the three colon cancer cell lines examined. Conclusion: LBH589 enhances TRAIL-induced apoptosis in human colon cancer cell lines, especially those resistant to TRAIL-induced apoptosis. %U https://ar.iiarjournals.org/content/anticanres/31/10/3385.full.pdf